The new Phase 3 clinical trial, MOMENTUM 1, is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study with an open-label extension phase of investigational drug, lorcaserin, as an adjunctive treatment in subjects with Dravet syndrome. Lorcaserin is a selective serotonin 5-HT2c receptor agonist. Stimulation of 5-HT2c receptors with lorcaserin may increase GABA-mediated inhibition and result in reduced seizure activity in Dravet syndrome patients.
Additional information about MOMENTUM 1 study can be found on clinicaltrials.gov
If you are interested in learning more about the MOMENTUM 1 study or are considering potential participation, please contact:
LaToya King, NYU Comprehensive Epilepsy Centre
Tel: 646-558-0838 Email: Latoya.King@nyulangone.org